Abstract
DE ANGELIS, L., AND C. FURLAN. The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test. PHARMACOL BIOCHEM BEHAV 65(4) 649–653, 2000.—The present study was designed to investigate the putative anxiolytic effects of moclobemide (MOC), a reversible inhibitor of type A monoamine oxidase enzyme (RIMA) antidepressant, in an experimental model of anxiety in mice. The test selected was the light/dark aversion test. In the present investigation, an anxiogenic-like behavior was induced by light, alone as the stimulus (standard version of the test) or by pretreatment with a subconvulsant dose of pentylenetetrazole (PTZ) (15 mg/kg IP) 45 min before testing (“enhanced” version of the test). In mice, the effect of repeated administration for 2 weeks of MOC (0.5, 1, and 5 mg/kg IP) was compared with those of selegiline (SEL) (5, 10, and 20 mg/kg IP), an irreversible and selective MAO-B inhibitor. For comparative purpose, the chronic effect of an established reference anxiolytic, such as lorazepam (LOR) (0.025, 0.05, and 0.10 mg/kg IP), was also evaluated. Results demonstrated that PTZ-treated mice showed a decrease in the number of transitions as well as in the time spent in the lit area, when compared with vehicle controls, an effect characteristic of an anxiogenic response. This anxiogenic-like behavior was reduced by chronic administration of LOR as well as MOC, suggesting an anxiolytic-like effect (as shown in the “standard” version of the test). In addition, the increased aversion of mice for the light compartment of the light/dark box was significantly reduced compared to PTZ-treated mice or vehicle controls. SEL failed to significantly alter the anxiogenic-like behavior induced by subconvulsant doses of PTZ. These data provide additional evidence for the anxiolytic-like effects of MOC administered chronically in the mouse.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.